CSTI-300 is under clinical development by ConSynance Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CSTI-300’s likelihood of approval (LoA) and phase transition for Irritable Bowel Syndrome took place on 14 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CSTI-300 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CSTI-300 is under development for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) and IBS with alternating constipation and diarrhea (IBS-M). The drug candidate is administered orally in the form of solution. The drug candidate acts by targeting 5-hydroxytryptamine receptor 3.
ConSynance Therapeutics overview
ConSynance Therapeutics, formerly Concerted Therapeutics is a drug discovery company that concentrates on the development of new therapeutic solutions for unmet medical needs. The company offers pipeline programs such as CSTI-100, CSTI-200, and CSTI-300, among others. It develops pipeline programs for nonalcoholic steatohepatitis and inflammatory bowel disease; type-2 diabetes and alzheimer’s disease, irritable bowel syndrome; and CNS diseases, among others. ConSynance Therapeutics offers several preclinical and early development programs in metabolic, autoimmune and digestive, among others. The company works in partnership with other pharma companies for drug development. ConSynance Therapeutics is headquartered in Rensselaer, New York, the US.
Quick View CSTI-300 LOA Data
|Highest Development Stage|